GPT Healthcare delivered robust fourth-quarter results with consolidated net profit rising 13.03% year-on-year to ₹14.57 crore in Q4 FY26, compared with ₹12.89 crore in the corresponding period last year. According to reports from Business Standard, revenue from operations jumped 24.62% YoY to ₹126.37 crore in the quarter ended March 31, 2026. However, profit before tax declined 3.11% to ₹15.86 crore, compared with ₹16.37 crore in the year-ago period. The latest data from The Economic Times confirms revenue growth accelerated to 26%, indicating strong volume growth in patient footfalls and diagnostic services across the network.
While the company achieved strong top-line growth, EBITDA margins contracted by 190 basis points to 18.5% from 20.4% year-on-year due to rising operational costs. As reported by The Economic Times, this margin compression stems from higher medical staff costs and the cost of consumables which rose faster than the company's billing rates. The decline in EBITDA margin highlights a shift in case-mix or increased promotional spending during the quarter, with operational expenses outpacing price hikes. Despite these challenges, the company maintains profitability, showcasing resilient business fundamentals in the competitive healthcare landscape.
For the full financial year FY26, the company reported a 15.42% decline in net profit to ₹42.22 crore, even as revenue from operations increased 16.07% to ₹472.55 crore. As reported by Business Standard, this contrasting performance between quarterly and annual results highlights the company's operational challenges during the fiscal year despite strong Q4 performance.
The company's board has recommended a final dividend of ₹1.50 per equity share of face value ₹10 each (15%) for FY26, subject to shareholder approval at the ensuing 37th annual general meeting. According to Business Standard, the dividend, if approved, will be paid within 30 days of declaration, with the record date fixed as July 30, 2026. The stock counter slipped 2.51% to ₹138.10 on the BSE following the results announcement.
GPT Healthcare operates as the healthcare arm of the GPT Group and currently owns and operates over 561 beds spread across four state-of-the-art multi-specialty hospitals in the eastern part of the country under the brand name ILS Hospitals. As reported by The Economic Times, the growth to ₹126 crore was primarily driven by higher patient volumes and an increase in the number of complex surgeries performed across the ILS Hospitals network. The company successfully completed its IPO in February 2024, raising funds to pare down debt and fund expansion, with recent emphasis on expanding nursing schools and enhancing diagnostic capabilities in its flagship Kolkata facilities.
